We next asked whether the antagonistic effect of SU5416, a VEGFR-2 tyrosine kinase inhibitor, on biological activities of VEGF-A could be attributed to the inhibition of FLJ10540 protein overexpression induced by VEGF-A in lung cancer cells. The gene discussed is VEGFA; the disease is lung cancer.